Early intervention is not required in patients with asymptomatic myeloma (1).
The overall risk of progression to symptomatic myeloma during the first 5 years is around 10% per year but declines in subsequent years.
Monitoring of asymptomatic myeloma patients include the following:
A repeat of bone marrow examination and skeletal imaging should be considered before starting therapy in these patients (1).
The ability of immunomodulatory drugs to delay the progression from asymptomatic to symptomatic myeloma is under investigation (2).
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page